Shenyang, China

Huimin Cai

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: University of California, Youhealth Biotech, Limited. Active years: 2019.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Huimin Cai in Vision Disorder Treatments

Introduction

Huimin Cai is an accomplished inventor based in Shenyang, China. He has made significant contributions to the field of vision disorders through his innovative research and patent developments. His work focuses on utilizing sterols to address various vision-related issues.

Latest Patents

Huimin Cai holds a patent for "Compositions and methods to treat vision disorders." This invention provides compositions that include a pharmaceutically effective amount of lanosterol, which can be used to treat and prevent vision disorders in subjects. The patent outlines several embodiments, including the use of lanosterol to treat cataracts or blindness/impaired vision. Additionally, it describes how lanosterol can dissolve amyloid-like fibrils of crystallin proteins, which are often associated with vision disorders.

Career Highlights

Throughout his career, Huimin Cai has worked with notable organizations, including Youhealth Biotech, Limited and the University of California. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Huimin has collaborated with several professionals in his field, including Kang Zhang and Rui Hou. These partnerships have further enriched his research and innovation efforts.

Conclusion

Huimin Cai's work in developing treatments for vision disorders showcases his dedication to improving healthcare through innovation. His patent on the use of lanosterol represents a significant step forward in addressing vision-related challenges.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…